Item 7.01 Regulation FD Disclosure.
On
The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01. Other Events. BDTX-1535
On
BDTX-189
The Company also announced that, due to the rapid evolution of the treatment landscape in non-small cell lung cancer harboring either EGFR or HER2 Exon 20 insertion mutations, the Company has decided to enroll additional patients into the MasterKey-01 Phase 1 safety expansion cohort to obtain more clinical data and inform future development of BDTX-189. The Company expects to provide further guidance on the BDTX-189 program in 2022.
Financial Guidance
The Company announced that it ended 2021 with approximately
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits: Exhibit No. Description Press Release issued byBlack Diamond Therapeutics, Inc. , dated January 99.1 10, 2022. Corporate Presentation ofBlack Diamond Therapeutics, Inc. , dated 99.2January 10, 2022 . Cover Page Interactive Data File (embedded within the Inline XBRL document 104 contained in Exhibit 104).
© Edgar Online, source